Eye (London, England)۲۰۲۵۲۰ استنادنمایه شده در PubMed
Imran Karim Janmohamed, Adeel Mushtaq, Jamil Kabbani, Simeon Harrow, Aaruran Nadarajasundaram, Anibe Ata, Henrietta Monye, Zakariya Jarrar, Shabeeba Hannan, Luke Membrey
چکیده
Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2, has shown promise in treating neovascular age-related macular degeneration (nAMD). This study evaluates 1-year outcomes of faricimab in treatment-experienced nAMD patients. This single-centre retrospective cohort study included…
متن کامل چکیده در سایت ناشر در دسترس است.
DOI: 10.1038/s41433-025-03616-5